Pyoderma gangrenosum complicating non-Hodgkin's lymphoma

Mahood, John M.; Sneddon, I. B.

doi:10.1111/j.1365-2133.1980.tb05696.x

Cited by 36 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several lines of evidence supporting an immunologic etiology of PG. For one, as mentioned above, patients often have a coexisting immunemediated disease such as IBD or inflammatory arthritis (RA, ankylosing spondylitis, or other seronegative arthritis) (23)(24)(25)(26)(27)(28)(29)(30). Second, patients treated with immune modifying medications for other conditions rarely develop PG; for example, there have been separate case reports of patients developing PG in the setting of infliximab or granulocyte-macrophage colony-stimulating factor (GMCSF) therapy (31,32).…”

Section: Pathophysiologymentioning

confidence: 99%

Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review

Patel¹,

Fitzmaurice²,

Duong³

et al. 2015

Acta Derm Venerol

106

115

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is an inflammatory disease characterized by painful skin ulcerations with undermined and erythematous borders. The etiology of PG is not well understood, but it is generally considered to be an aberrant immune response characterized by a dermal neutrophilc infiltrate. Given the existence of only a few PG clinical trials, treatment options are largely based upon anecdotal data and small case studies. In addition to classic immunosuppressive medications, PG has been reported to respond well to the anti-TNF agents, infliximab, etanercept, adalimumab. Newer biologics such as ustekinumab (anti-IL-23), ixekizumab (anti-IL-17) and brodalumab (anti-IL-17R) are promising given the effect of IL-17 on neutrophil migration. However, the effectiveness of these newer agents remains to be rigorously evaluated. Multi-drug regimens have not been well described in the literature but are an excellent alternative for patients with refractory disease. Herein, we provide a comprehensive review of the pathophysiology of PG and of the different treatments available for managing PG patients, including the theoretical benefit of initiating multidrug regimens. We also provide one possible treatment algorithm for patients with refractory disease and give examples of refractory PG cases successfully treated with multidrug regimens.

show abstract

Section: Pathophysiologymentioning

confidence: 99%

Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review

Patel¹,

Fitzmaurice²,

Duong³

et al. 2015

Acta Derm Venerol

106

115

View full text Add to dashboard Cite

show abstract

“…In as many as 70% of cases, PG may be associated with a variety of diseases, including inflammatory bowel disease, 2,87 seropositive or seronegative arthritis, 88–90 multiple myeloma, 91 paraproteinemia (particularly IgA), 12,92–94 diverticulitis, 95 pulmonary disease, 96–98 malignancies (particularly leukemia), 8,15,22,99–104 and other conditions 14,81,105–113 . Yet, diagnosis of PG should not rely on this criterion alone because these diseases may be associated with ulcers due to other conditions 1 …”

Section: Associated Diseasesmentioning

confidence: 99%

Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Ulcerative variant of pyoderma gangrenosum was described for involvement of plasmocytoma, mainly IgA 2,16 rarely with IgG‐type 17 . Occurrence of pyoderma gangrenosum was common due to Hodgkin and non‐Hodgkin lymphomas 18,19 T‐cell lymphomas 20 and carcinomas of the colon, urinary bladder, breast, bronchial, ovaries and suprarenal glands 21…”

Section: Discussionmentioning

confidence: 99%

Pyoderma gangrenosum coexisting with acute myelogenous leukaemia

Krauze¹,

Brzeźińska-Wcisło²,

Kamińska‐Winciorek³

et al. 2005

Acad Dermatol Venereol

View full text Add to dashboard Cite

The frequency of occurrence of malignant neoplasms in the cases of pyoderma gangrenosum is not exactly determined, but it can be assessed to be at 7%. The aim of the study was to report a 26-year-old male patient with pyoderma gangrenosum coexisting with acute myelogenous leukaemia. The first skin lesions on both tibia occurred in June 2001. Prior to the proper diagnosis of pyoderma gangrenosum, the patient was treated surgically. Because of the dramatic dermatological and general condition in November 2001, the patient was admitted to the Dermatological Department of the Silesian Medical Academy in Katowice where the diagnosis of pyoderma gangrenosum was established. On the clinical and biochemical picture, the diagnosis of pyoderma gangrenosum within acute myelogenous leukaemia was made. Initially, cyclosporin A 200 mg orally per day in the therapy of pyoderma gangrenosum was administered to achieve a slight clinical improvement. Although chemotherapy leukaemia was performed, the patient died after 4 months of the confirmation of the acute myelogenous leukaemia diagnosis.

show abstract

Pyoderma gangrenosum complicating non-Hodgkin's lymphoma

Abstract: A case of pyoderma gangrenosum which occurred in a patient with non-Hodgkin's lymphoma is described. The lesion started in the foot where dye was introduced for a lymphangiogram.

Cited by 36 publications

References 7 publications

Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review

Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review

Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria

Pyoderma gangrenosum coexisting with acute myelogenous leukaemia

Contact Info

Product

Resources

About